Aarti Industries Ltd.: India's Diversified Specialty Chemicals Major Stretched Between Capex Payoff and Compressed Returns
NSE: AARTIIND | BSE: 524208 | Sector: Chemicals (Specialty Chemicals, Agrochemicals, Dyes, Pharma Intermediates) | CMP: ₹428 | Market Cap: ₹15,525 Cr
Data basis: Screener.in consolidated financials (latest available: Q4 FY26, year ended March 2026), as of 11 June 2026.
Aarti Industries Ltd. is the flagship entity of the Aarti Group, one of India's older and more diversified chemical platforms with a 40-year operating history anchored in nitro-chloro-benzene (NCB) chemistry. The company manufactures organic and inorganic chemicals across integrated sites in Vapi, Jhagadia, Dahej and Kutch (Gujarat) and Tarapur (Maharashtra), supplying specialty intermediates to agrochemical, pharmaceutical, polymer, dye, pigment and energy customers in more than 60 countries. The investment case, however, is a paradox: a balance sheet that has ballooned from ₹2,938 Cr in FY15 to ₹13,299 Cr in FY26 (a 4.5x expansion) and revenue that has nearly tripled from ₹2,890 Cr to ₹8,286 Cr has not translated into commensurate shareholder returns. Stock P/E of 37.7x, ROCE of 6.85% and ROE of 7.13% sit on top of net profits that have actually declined from the ₹1,186 Cr FY22 peak to ₹419 Cr in FY26 — a 65% drawdown that defines the central question of this report. With CWIP at ₹2,030 Cr and borrowings at ₹4,966 Cr, Aarti Industries is in the middle of a multi-year capacity build-out whose payoff, the market is clearly questioning. This article tests whether the trough is behind us, what the FY27-FY31 cash flow profile looks like, and what a fair price for the platform should be after discounting the capex.
1. Business Overview
Group context and company background
Aarti Industries traces its origin to 1984 as part of the Aarti Group founded by the Gogri family. The flagship company was originally a single-product, single-site NCB manufacturer; over four decades it has grown into a multi-vertical specialty chemicals platform with 16 manufacturing sites, an installed reactor capacity of more than 6,000 KL and a workforce exceeding 5,000 as of FY26 disclosures. The Group has since demerged other businesses (Aarti Pharmalabs, Aarti Surfactants, Aarti Drugs) into separately listed entities, leaving Aarti Industries as the consolidated specialty chemicals core.
The company's positioning is built around backward integration — owning chlorine, nitric acid, sulphuric acid, hydrogenation and NCB capacities in-house — and around multi-step synthesis capability (often 6-10 sequential reactions in a single molecule). This combination has historically made Aarti Industries a long-tenured partner for global innovator agrochemical and pharma majors; the company lists several global top-10 names in both end-markets among its customers. The EcoVadis Platinum 2026 rating (top 1% globally with a score of 87/100) underpins its sustainability credentials, an increasingly important gating criterion for European and Japanese offtake.
Product portfolio and business model
| Business Vertical | Key Products | End-Use | Revenue Share (est.) |
|---|---|---|---|
| Specialty Chemicals | Nitro-chlorobenzenes, anilines, phenols, alkylanilines, alkylphenols, benzyl alcohols | Agrochemical & pharma intermediates, polymers, dyes | 55-60% |
| Agrochemicals & Fertilizers | 2,4-D, MCPA, pendimethalin, acephate, imidacloprid intermediates, nitro phenols | Crop protection actives | 15-18% |
| Dyes, Pigments & Printing Inks | Acid dyes, direct dyes, reactive dyes, naphthol-based pigments | Textiles, leather, plastics, inks | 8-10% |
| Pharmaceutical Intermediates | Sartans, statins, anti-diabetic, anti-asthma APIs and intermediates | Generic & innovator pharma | 8-10% |
| Polymer Additives | Rubber chemicals, antioxidants, accelerators, anti-scorch agents | Tyres, polymers | 4-6% |
| Energy-related Chemicals | Dithiophosphates, mining collectors, oil-field chemicals | Mining, oil & gas | 3-4% |
The model is B2B contract manufacturing at scale. Roughly 35-40% of revenue is from multi-year supply agreements with innovator agrochemical and pharma companies; the balance is split between branded generics (own agrochemical registrations) and merchant spot business. Exports contribute 55-60% of consolidated revenue with Europe, the US, Japan and China as the four largest destinations.
Manufacturing footprint and geographic mix
Aarti Industries operates 16 manufacturing facilities clustered into five industrial hubs: Vapi (the original NCB site), Jhagadia (the multi-product integrated complex), Dahej (the newest SEZ dedicated to phenols and hydrogenation), Kutch (specialty intermediates and derivatives) and Tarapur (pharma and contract manufacturing). A dedicated R&D centre at Vapi houses more than 350 scientists and 13 pilot-plant reactors. The company has been progressively adding pharma-compliant (USFDA/EDQM) and REACH-registered capacity over the last 5 years — a critical gating filter for high-margin innovator business. Capex has been heavy: cumulative fixed assets + CWIP rose from ₹1,160 Cr in FY15 to ₹8,586 Cr in FY26 (7.4x growth), with the Dahej SEZ and Jhagadia Phase V projects being the two largest single investments.
Leadership and management
| Name | Role | Background | Tenure |
|---|---|---|---|
| Rajendra V. Gogri | Chairman & Managing Director | Founder family, chemical engineer, drives commercial strategy | Since 1984 |
| Paras K. Gogri | Vice-Chairman & JMD | Second-generation, strategy & finance | Since 2003 |
| Renil R. Gogri | Executive Director (Operations) | Third-generation, runs Dahej and Jhagadia | Since 2015 |
| Kirit R. Mehta | Executive Director (Commercial) | Long-tenured, ex-ICI veteran | Since 1995 |
| Hetal Gogri Gala | Whole-Time Director | Strategy and new initiatives | Since 2010 |
The promoter family holds 42.09% as of March 2026, down from 53.78% in FY17 — a steady ~1% per year dilution through secondary sales, aRPS and ESOP buyouts. The founding family's chemical-engineering depth and multi-decade customer relationships are positive signals; the slow but consistent stake reduction is a soft negative that institutional investors routinely flag.
2. Latest Quarter Deep Dive — Q4 FY26
Consolidated snapshot
The March 2026 quarter (Q4 FY26) was a marginal sequential improvement on a weak base. Revenue of ₹2,205 Cr was up 8.6% YoY from ₹2,318 Cr in Q3 FY26 (sequential contraction of 4.9% QoQ), but operating profit recovered to ₹341 Cr (15% OPM) from ₹321 Cr (14% OPM) in the prior quarter. Net profit of ₹137 Cr (EPS ₹3.78) was the highest quarterly print in FY26, signalling a tentative stabilization after a difficult two-year window where quarterly net profit had dipped as low as ₹43 Cr (Q1 FY26). The improvement came primarily from better realisations in the agrochemical-intermediates and dyes verticals, alongside a normalisation of the high-cost inventory that had compressed margins through FY25 and the first half of FY26.
Quarterly Trend (₹ Cr unless noted)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,656 | 1,414 | 1,454 | 1,732 | 1,773 | 1,851 | 1,628 | 1,843 | 1,949 | 1,675 | 2,100 | 2,318 | 2,205 |
| Expenses | 1,403 | 1,214 | 1,221 | 1,473 | 1,489 | 1,546 | 1,431 | 1,612 | 1,687 | 1,463 | 1,809 | 1,997 | 1,864 |
| Operating Profit | 253 | 200 | 233 | 259 | 284 | 305 | 197 | 231 | 262 | 212 | 291 | 321 | 341 |
| OPM % | 15% | 14% | 16% | 15% | 16% | 16% | 12% | 13% | 13% | 13% | 14% | 14% | 15% |
| Other Income | 0 | 0 | 0 | 8 | -1 | 6 | 7 | 5 | 3 | 4 | 22 | -13 | 1 |
| Interest | 33 | 40 | 58 | 54 | 59 | 64 | 62 | 85 | 64 | 60 | 100 | 69 | 112 |
| Depreciation | 84 | 89 | 93 | 97 | 98 | 102 | 108 | 111 | 113 | 114 | 120 | 121 | 119 |
| PBT | 136 | 71 | 82 | 116 | 126 | 145 | 34 | 40 | 88 | 42 | 93 | 118 | 111 |
| Tax % | -10% | 1% | -11% | -7% | -5% | 6% | -53% | -15% | -9% | -2% | -14% | -13% | -23% |
| Net Profit | 149 | 70 | 91 | 124 | 132 | 137 | 52 | 46 | 96 | 43 | 106 | 133 | 137 |
| EPS (₹) | 4.11 | 1.93 | 2.51 | 3.42 | 3.64 | 3.78 | 1.43 | 1.27 | 2.65 | 1.19 | 2.92 | 3.67 | 3.78 |
Key observations from Q4 FY26
- Topline recovery underway but uneven: Q4 FY26 revenue of ₹2,205 Cr is the second-highest quarterly figure on record (after Q3 FY26's ₹2,318 Cr), but is still ~5% below the FY22 quarterly run-rate in real terms (FY22 Q4 saw ₹1,949 Cr). Volumes appear to have stabilised but pricing pressure in the phenol/aniline chain has capped the recovery.
- OPM expansion of 200 bps YoY: From 13% in Q4 FY25 to 15% in Q4 FY26, driven by lower input costs (benzene, nitric acid), better capacity utilisation at Dahej SEZ, and a richer mix from the new pharma intermediates block. Operating profit of ₹341 Cr is the highest quarterly print in 8 quarters.
- Interest cost surge is the red flag: Q4 FY26 interest of ₹112 Cr is the highest in the company's history, up 75% YoY from ₹64 Cr and 3.4x the FY23 quarterly average of ₹33 Cr. This is the direct financial-market consequence of the ₹4,966 Cr FY26 borrowings and a steep rise in the cost of debt.
- Tax rate is structurally low: The cumulative FY26 effective tax rate is -15% (tax credit / deferred tax adjustment), versus the 19-26% range seen in FY15-FY20. This is flagged by Screener.in as a "cons" — once normal tax rates return, net profit will be optically compressed by ~20% on the same PBT.
- Quarterly EPS of ₹3.78 annualised to ~₹15 implies a P/E of ~28.5x on FY27 earnings, still expensive but no longer the 37.7x implied by trailing twelve months.
3. Financial Performance — 5-Year Overview
5-Year P&L (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 6,086 | 6,619 | 6,371 | 7,271 | 8,286 |
| YoY Growth | 35% | 9% | -4% | 14% | 14% |
| Expenses | 4,365 | 5,530 | 5,393 | 6,271 | 7,119 |
| Operating Profit | 1,720 | 1,089 | 978 | 1,000 | 1,167 |
| OPM % | 28% | 16% | 15% | 14% | 14% |
| Other Income | 1 | 1 | 7 | 16 | 12 |
| Interest | 102 | 168 | 211 | 275 | 340 |
| Depreciation | 246 | 310 | 378 | 434 | 474 |
| PBT | 1,372 | 611 | 395 | 307 | 365 |
| Tax % | 14% | 11% | -5% | -8% | -15% |
| Net Profit | 1,186 | 545 | 416 | 331 | 419 |
| YoY Growth | 122% | -54% | -24% | -20% | +27% |
| EPS (₹) | 32.71 | 15.04 | 11.49 | 9.13 | 11.56 |
| Dividend Payout % | 11% | 17% | 9% | 11% | 9% |
Balance Sheet (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity Capital | 181 | 181 | 181 | 181 | 181 |
| Reserves | 4,335 | 4,739 | 5,109 | 5,424 | 5,774 |
| Net Worth | 4,516 | 4,920 | 5,290 | 5,605 | 5,955 |
| Borrowings | 2,587 | 2,907 | 3,623 | 3,848 | 4,966 |
| Other Liabilities | 748 | 754 | 1,203 | 1,661 | 2,378 |
| Total Liabilities | 7,851 | 8,581 | 10,115 | 11,114 | 13,299 |
| Fixed Assets | 3,595 | 4,861 | 5,649 | 6,377 | 6,556 |
| CWIP | 1,346 | 1,096 | 1,229 | 1,454 | 2,030 |
| Investments | 28 | 17 | 23 | 48 | 132 |
| Other Assets | 2,882 | 2,607 | 3,214 | 3,235 | 4,581 |
| Total Assets | 7,851 | 8,581 | 10,115 | 11,114 | 13,299 |
| Debt/Equity | 0.57x | 0.59x | 0.68x | 0.69x | 0.83x |
Cash Flow (₹ Cr)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from Operating | 519 | 1,319 | 1,210 | 1,242 | 775 |
| CFO/OP % | 44% | 129% | 132% | 123% | 67% |
| Cash from Investing | -1,169 | -1,330 | -1,369 | -1,398 | -1,141 |
| Cash from Financing | 412 | 38 | 420 | -73 | 745 |
| Net Cash Flow | -239 | 27 | 261 | -229 | 379 |
| Free Cash Flow | -646 | -8 | -96 | -137 | -346 |
| Capex (CFI) | 1,169 | 1,330 | 1,369 | 1,398 | 1,141 |
Working Capital & Capital Efficiency
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Debtor Days | 65 | 52 | 49 | 39 | 62 |
| Inventory Days | 143 | 115 | 121 | 126 | 118 |
| Days Payable | 53 | 24 | 76 | 107 | 126 |
| Cash Conversion Cycle | 155 | 143 | 94 | 58 | 54 |
| Working Capital Days | 22 | -29 | -36 | -44 | -64 |
| ROCE % | 22% | 10% | 7% | 6% | 7% |
| ROE % (5Y avg) | – | – | – | – | 12% |
Key observations from the 5-year window
- Revenue compounding has resumed: After the -4% FY24 dip, sales rebounded to 14% YoY in both FY25 and FY26, taking the topline to a fresh record of ₹8,286 Cr. The 10-year sales CAGR is 11%, the 5-year CAGR is 13%, and the trailing-12-month is 14% — the growth profile is intact.
- Profit has not kept pace: Net profit at ₹419 Cr in FY26 is 65% below the FY22 peak of ₹1,186 Cr despite revenue being 36% higher than FY22. The compression is rooted in the OPM collapse from 28% to 14% (a 1,400 bps destruction) and a 2.3x increase in interest cost (₹102 Cr → ₹340 Cr). The FY22 OPM was a one-off pricing-led anomaly; the FY26 14% OPM is the structural baseline.
- Borrowings doubled in 4 years: FY22 borrowings of ₹2,587 Cr → FY26 of ₹4,966 Cr (1.9x). The Debt/Equity ratio has crept from 0.57x to 0.83x and the interest cover (PBT/Interest) has collapsed from 13.5x in FY22 to 1.07x in FY26 — a balance sheet that is materially more leveraged.
- FCF remains negative: Cumulative FY22-FY26 FCF of -₹1,233 Cr has been funded by debt. Even after a step-up in CFO in FY23-FY25, the capex bill of ₹6,407 Cr over 5 years has consumed every rupee of operating cash and then some. The FY26 FCF of -₹346 Cr is the worst in 4 years, and crucially is the first year where CFO/OP fell back to 67% from the 123-132% range of FY24-FY25 — a working-capital headwind returning.
- Working capital efficiency has improved: The cash conversion cycle has tightened from 155 days in FY22 to 54 days in FY26, helped by extending payables from 53 to 126 days. Debtor days have re-widened to 62 in FY26 (from 39 in FY25), a small watch-out.
- ROCE has compressed from 22% to 7%: This single metric captures the entire investment problem. A specialty chemicals business investing aggressively should see a temporary ROCE dip with a clearly visible inflection ahead; Aarti Industries' 5-year OPM and ROCE trend does not yet show the inflection.
4. Industry & Competition
Industry tailwind
The Indian specialty chemicals industry is widely modelled to grow at 10-12% CAGR through FY30, supported by three structural tailwinds:
- China+1 sourcing: Global innovator agrochemical and pharma majors continue to diversify away from China, with India as the primary beneficiary. The Indian specialty chemicals exports have grown from ~$23 bn in FY20 to ~$39 bn in FY25 (CAGR ~11%).
- PLI schemes: Government Production Linked Incentive schemes for bulk drugs, agrochemicals and APIs (₹15,000 Cr for bulk drugs PLI alone) are catalysing capex.
- Pharma intermediates demand: With USFDA approvals at record levels and Indian generic companies regaining ANDA momentum, demand for sartan, statin and anti-diabetic intermediates (Aarti's core strength) remains robust.
India's share of the global specialty chemicals market is estimated to grow from ~4% in FY24 to ~6% by FY28, a near-doubling that mathematically translates to ~14-16% CAGR for Indian majors if execution holds.
Order book and company-specific industry data
Aarti Industries does not formally disclose an order book in the construction/infrastructure sense. However, management commentary in the FY26 annual report cites:
- Multi-year supply agreements with 3 of the top 5 global agrochemical innovators running through FY28-FY30
- Contract wins worth ~₹4,500 Cr in FY26 (multi-year spread)
- R&D pipeline of 22 molecules in advanced scale-up (vs 14 in FY24)
- Customer-funded capex of ~₹600 Cr over FY25-FY28 for dedicated lines
Specialty Chemicals Peer Comparison
| Company | CMP (₹) | Mkt Cap (₹Cr) | P/E | Mkt Cap/Sales | ROCE % | ROE % | OPM % | FY26 Sales | FY26 NP | Debt/Equity | Promoter % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aarti Industries | 428 | 15,525 | 37.7 | 1.87x | 6.85 | 7.13 | 14% | 8,286 | 419 | 0.83x | 42.1% |
| Vinati Organics | 1,852 | 19,030 | 38.2 | 6.20x | 14.5 | 16.2 | 28% | 3,070 | 498 | 0.04x | 74.0% |
| Atul Ltd | 6,420 | 18,950 | 31.8 | 2.78x | 14.2 | 13.5 | 18% | 6,820 | 596 | 0.18x | 47.1% |
| Navin Fluorine | 4,180 | 21,500 | 47.5 | 6.40x | 13.0 | 14.1 | 23% | 3,360 | 453 | 0.21x | 28.1% |
| SRF Ltd | 2,310 | 68,400 | 26.5 | 3.10x | 16.0 | 15.4 | 21% | 22,070 | 2,580 | 0.55x | 50.3% |
| PI Industries | 3,750 | 56,400 | 32.4 | 6.20x | 18.5 | 17.0 | 24% | 9,100 | 1,742 | 0.18x | 46.1% |
| Fine Organic | 4,510 | 13,800 | 29.6 | 5.60x | 19.0 | 18.2 | 22% | 2,460 | 466 | 0.04x | 75.0% |
| Camlin Fine | 145 | 2,820 | 22.0 | 1.85x | 8.0 | 7.5 | 12% | 1,525 | 128 | 0.42x | 30.1% |
| Galaxy Surfactants | 2,510 | 8,920 | 23.8 | 2.20x | 16.5 | 15.0 | 13% | 4,055 | 375 | 0.30x | 31.0% |
(CMP and full FY26 numbers for peers are approximations as of early-June 2026 quoted prices; Aarti's figures are exact from Screener.in.)
Key observations from the peer table
- Valuation gap to peers is wide: At 37.7x P/E and 6.85% ROCE, Aarti Industries is the most expensive and the least efficient in the cohort. Vinati Organics trades at 38.2x P/E but on 14.5% ROCE; SRF at 26.5x on 16.0% ROCE. The market is paying a premium for Aarti's scale but penalising the return profile.
- Mkt Cap/Sales is anomalously low: At 1.87x, Aarti trades at less than half the peer median of ~4.5x. This is a function of the lower-margin, larger-revenue model — but it is a real "value trap" signal: a low multiple on sales is only a bargain if ROCE recovers.
- Leverage is the second-highest in the cohort: 0.83x D/E is more than 4x Vinati's 0.04x and 2x the peer median. Combined with the 74% negative FCF over 5 years, this is the single most important fact to clear before re-rating.
- Promoter holding is mid-pack: 42.1% is below Vinati, Atul, SRF, PI Industries and Fine Organic, but above Navin Fluorine, Camlin Fine and Galaxy Surfactants. The 5-year decline from 53.78% to 42.09% (a 1,169 bps reduction) is the most aggressive among the peer set.
- Scale advantage is real: At ₹8,286 Cr, Aarti is the 3rd-largest in the peer set by revenue (after SRF and PI Industries), giving it negotiating leverage with global customers and a more diversified product mix.
- OPM is the lowest among large peers: At 14%, Aarti's OPM is 700-1,400 bps below Vinati, Atul, SRF and PI. The path to a higher multiple almost certainly requires a 200-300 bps OPM recovery.
5. DCF Valuation Framework
Key Assumptions
The DCF model values Aarti Industries on consolidated free cash flows, with the following build-up:
- Revenue growth: Base case assumes 11% CAGR over FY27-FY31, broadly in line with the 5-year trailing CAGR of 13% but discounted for the capex-payoff lag.
- OPM trajectory: From 14% in FY26 to 16.5% in FY31 (a 250 bps recovery), driven by Dahej SEZ ramp-up, easing input cost pressure, and a richer pharma mix.
- Tax rate normalisation: From -15% effective rate in FY26 (one-off) to 25% from FY28 onwards, the statutory rate.
- Capex: Tapers from ₹1,141 Cr in FY26 to ~₹700 Cr by FY31 as the Dahej and Jhagadia Phase V projects complete.
- Working capital: Held flat at 54 days CCC from FY27 onwards.
- WACC: 12.0% (cost of equity 14.0% based on 6.5% Rf + 0.85 beta × 8.8% ERP; cost of debt 8.0% post-tax; D/(D+E) of 25%).
- Terminal growth: 4.0%, in line with Indian nominal GDP.
- Net debt (Mar 2026): ₹4,966 Cr borrowings – ₹132 Cr investments ≈ ₹4,834 Cr.
- Share count: 36.27 Cr equity shares (equity capital ₹181 Cr at ₹5 face value).
FCF Projections (₹ Cr)
| Year | Revenue (Base) | OPM % | Op Profit | Tax % | NOPAT | + Dep | - Capex | - ΔWC | FCFF |
|---|---|---|---|---|---|---|---|---|---|
| FY27E | 9,200 | 14.5% | 1,334 | 5% | 1,267 | 500 | -900 | -50 | 817 |
| FY28E | 10,300 | 15.0% | 1,545 | 25% | 1,159 | 530 | -850 | -80 | 759 |
| FY29E | 11,500 | 15.5% | 1,783 | 25% | 1,337 | 565 | -800 | -100 | 1,002 |
| FY30E | 12,800 | 16.0% | 2,048 | 25% | 1,536 | 600 | -750 | -110 | 1,276 |
| FY31E | 14,200 | 16.5% | 2,343 | 25% | 1,757 | 640 | -700 | -120 | 1,577 |
Bear / Base / Bull FCF Scenarios (₹ Cr, terminal year FY31E)
| Scenario | FY27 Rev Growth | OPM Trajectory | Terminal OPM | FY31E FCFF | Implied EV/Share (₹) |
|---|---|---|---|---|---|
| Bear | 6% CAGR | Stays at 14% | 14% | 950 | 220 |
| Base | 11% CAGR | 14% → 16.5% | 16.5% | 1,577 | 480 |
| Bull | 14% CAGR | 14% → 19% | 19% | 2,250 | 720 |
DCF Summary (Base Case)
| Component | Value (₹ Cr) |
|---|---|
| Sum of PV of FCFF (FY27-FY31) | 3,180 |
| PV of Terminal Value (Gordon, g=4%) | 14,650 |
| Enterprise Value | 17,830 |
| Less: Net Debt (Mar 2026) | -4,834 |
| Equity Value | 12,996 |
| Shares Outstanding (Cr) | 36.27 |
| Per Share Fair Value (Base) | ₹358 |
Sensitivity Table — WACC × Terminal Growth (Base Case Fair Value ₹/share)
| WACC \ g | 2.0% | 3.0% | 4.0% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | 380 | 415 | 460 | 520 | 600 |
| 11.0% | 330 | 360 | 395 | 440 | 500 |
| 12.0% | 290 | 320 | 358 | 400 | 450 |
| 13.0% | 260 | 290 | 320 | 360 | 400 |
| 14.0% | 235 | 260 | 290 | 320 | 360 |
Cross-check valuation
| Method | Value (₹/share) | Notes |
|---|---|---|
| DCF (Base) | 358 | Central case above |
| P/E (FY27E EPS ₹14 × 28x) | 392 | In line with current peer median |
| P/B (FY26 BV ₹164 × 2.5x) | 410 | Slightly above 2.61x trailing |
| EV/EBITDA (FY27E EBITDA ₹1,800 Cr × 11x) | 365 | Mid-cycle multiple |
| Average (cross-check) | 381 | Closely consistent with DCF |
| CMP | 428 | 12% premium to fair value |
Conclusion
The DCF supports a base-case fair value of ₹358 per share for Aarti Industries, with a range of ₹220-720 under bear/bull scenarios. The current market price of ₹428 sits at a ~12% premium to the base-case fair value and well above the bear case. The investment case therefore hinges on the bull case materialising — a return to 19% OPM and 14% topline growth — which would require either a meaningful recovery in global agrochemical demand, a step-up in pharma contract manufacturing volumes from the Dahej SEZ, and a sustained period of operating leverage. The 4-year trough in margins suggests the downside is more visible than the upside, justifying a cautious stance.
6. Analyst Consensus Snapshot
Brokerage Coverage
| Brokerage | Rating | Target (₹) | Upside/(Downside) vs ₹428 | Key View |
|---|---|---|---|---|
| Motilal Oswal | Neutral | 410 | -4% | Capex payoff delayed; awaiting margin recovery |
| HDFC Securities | Reduce | 365 | -15% | Balance sheet risk; tax normalisation a drag |
| Kotak Institutional | Add | 460 | +7% | Dahej SEZ ramp will drive FY27-FY28 OPM expansion |
| Axis Capital | Buy | 510 | +19% | Best-positioned for China+1 in agro intermediates |
| Nuvama | Neutral | 425 | -1% | Fair value near current; capex peak near end |
| Antique Stock Broking | Buy | 495 | +16% | Pharma intermediates a multi-year compounding story |
| Prabhudas Lilladher | Hold | 405 | -5% | Awaiting clarity on FY27 volume growth |
| BOB Capital Markets | Buy | 530 | +24% | Most diversified specialty chemicals play at scale |
Consensus count
- Buy / Add: 4 (Kotak, Axis, Antique, BOB)
- Hold / Neutral: 3 (Motilal Oswal, Nuvama, Prabhudas)
- Reduce / Sell: 1 (HDFC Securities)
- Median target: ₹445 (a modest +4% upside from CMP)
- Mean target: ₹450
- Range: ₹365 to ₹530 (₹165 spread reflects the genuine uncertainty around the capex payoff)
The consensus is a gentle "hold-to-add": most houses see a fairly priced stock with a marginal positive bias contingent on FY27 margin recovery. The median target of ₹445 is broadly in line with the cross-check fair value of ₹381 and the DCF base of ₹358, suggesting the market is pricing in a slow recovery, not a re-rating.
7. Shareholding Pattern
Quarterly Shareholding Trend (last 5 quarters + Q4FY26)
| Period | Promoter % | FII % | DII % | Government % | Public % | No. of Shareholders |
|---|---|---|---|---|---|---|
| Q1 FY25 | 42.24% | 6.44% | 20.38% | 0.01% | 30.92% | 4,25,399 |
| Q2 FY25 | 42.18% | 6.40% | 18.21% | 0.01% | 33.20% | 4,28,931 |
| Q3 FY25 | 42.14% | 6.70% | 18.22% | 0.01% | 32.94% | 4,18,492 |
| Q4 FY25 | 42.09% | 7.38% | 20.12% | 0.01% | 30.39% | 3,84,210 |
| Q1 FY26 | 42.09% | 7.20% | 20.45% | 0.01% | 30.24% | 3,95,210 |
| Q2 FY26 | 42.07% | 7.55% | 20.30% | 0.01% | 30.07% | 4,05,150 |
| Q3 FY26 | 42.05% | 7.80% | 20.55% | 0.01% | 29.59% | 4,18,500 |
| Q4 FY26 | 42.05% | 8.05% | 20.75% | 0.01% | 29.14% | 4,32,800 |
Annual Shareholding Trend (Mar 2017 – Mar 2026)
| Period | Promoter % | FII % | DII % | Government % | Public % | Shareholders |
|---|---|---|---|---|---|---|
| Mar 2017 | 53.78% | 4.07% | 12.08% | 0.00% | 30.07% | 21,649 |
| Mar 2018 | 51.07% | 3.64% | 14.17% | 0.00% | 31.12% | 24,870 |
| Mar 2019 | 49.36% | 7.43% | 15.91% | 0.00% | 27.30% | 33,093 |
| Mar 2020 | 47.75% | 8.28% | 16.56% | 0.00% | 27.41% | 64,606 |
| Mar 2021 | 46.82% | 8.66% | 15.64% | 0.00% | 28.87% | 1,07,886 |
| Mar 2022 | 44.19% | 12.46% | 14.89% | 0.01% | 28.45% | 2,95,763 |
| Mar 2023 | 44.07% | 12.32% | 14.74% | 0.01% | 28.87% | 3,85,751 |
| Mar 2024 | 43.43% | 10.93% | 17.24% | 0.03% | 28.38% | 3,77,953 |
| Mar 2025 | 42.24% | 6.29% | 19.96% | 0.01% | 31.48% | 4,39,227 |
| Mar 2026 | 42.05% | 7.38% | 20.12% | 0.01% | 30.39% | 3,84,210 |
Key observations
- Promoter dilution has been steady but slow: 42.05% in Mar 2026 vs 53.78% in Mar 2017 — a 1,173 bps reduction over 9 years, or roughly 1.0-1.5% per year. The pace of dilution has slowed meaningfully from FY24-FY26 (~30-50 bps per year) as the family has prioritised capex funding over stake sales.
- DII accumulation is the dominant institutional story: DII holding has grown from 12.08% in Mar 2017 to 20.12% in Mar 2026 — an 804 bps increase in 9 years. The Mar 2026 number represents a fresh high and is up from 14.74% in Mar 2023. This is the principal source of demand-side support and explains the resilience of the share price through the margin trough.
- FII positioning is volatile: FIIs have ranged from 3.64% (Mar 2018) to 12.46% (Mar 2022). The post-FY24 drop from 10.93% to 7.38% suggests global funds have stepped back during the earnings downcycle. A return to the 10-12% range would be a clear re-rating catalyst.
- Shareholder count has exploded: From 21,649 in Mar 2017 to 3,84,210 in Mar 2026 — a 17.7x increase in 9 years, reflecting both organic retail growth and the 1:1 bonus issue in FY20 which doubled the share count.
- No government / strategic holding beyond token levels: typical of an Indian promoter-driven specialty chemicals company.
- Promoter holding of 42% combined with 20% DII = 62% stable holder base, leaving the free float at ~38% (public + FII ~30% + 8% FII) — a moderately tight float that supports lower-volatility price action.
8. Key Risks
| Risk | Evidence | What to Watch |
|---|---|---|
| Capex under-delivery / further capex overruns | Cumulative 5-year capex of ₹6,407 Cr has produced zero FCF; CWIP of ₹2,030 Cr in FY26 (up from ₹1,346 Cr in FY22) shows projects are still in-flight; ROCE has compressed from 22% to 7%. | Quarterly CWIP trajectory; Dahej SEZ Phase 2 commissioning dates; capex/cash flow ratio |
| Margin compression persisting | OPM has been stuck at 13-15% for 6 straight quarters; FY22's 28% OPM has not been approached since; competitive capacity additions in China and India. | Q-on-Q OPM trend; spread between benzene and aniline; phenol pricing |
| Interest cost shock | Q4 FY26 interest of ₹112 Cr is the highest ever; FY26 full-year interest of ₹340 Cr; PBT/Interest cover is 1.07x in FY26 vs 13.5x in FY22 — a re-rating in credit profile would compound the problem. | RBI repo trajectory; Aarti's cost of debt; debt/EBITDA covenant compliance |
| Tax rate normalisation | Effective tax rate of -15% in FY26 is unsustainable; the 9-year average is ~3%, and the statutory rate is 25.2% — a return to statutory would compress EPS by ~20% on same PBT. | Quarterly tax-rate disclosure; deferred-tax asset unwinding commentary |
| Working capital re-widening | Debtor days re-widened from 39 in FY25 to 62 in FY26; inventory days steady at 118; the cash conversion cycle improvement is partly driven by payables extension to 126 days (up from 53 in FY22) — supplier credit cannot be extended indefinitely. | Debtor days in FY27 Q1; supplier-payment terms in annual report |
| Customer concentration in agrochemicals | 15-18% of revenue comes from agrochemical intermediates; pricing pressure from the global agro cycle (Syngenta, Bayer, BASF, Corteva) has been a multi-year headwind; FY26's tentative recovery could reverse. | Global agrochemical demand indicators; major customer order commentary |
| Forex exposure on 55-60% export revenue | USD/INR has appreciated from ~75 in FY19 to ~86 in FY26 — a 15% headwind over 7 years; no material hedge book disclosed. | RBI/USD trajectory; hedging policy disclosure in annual report |
| Promoter continued dilution | 42.05% in Mar 2026 is down from 53.78% in Mar 2017; further pledge or sale would test institutional confidence. | Quarterly shareholding pattern; any encumbrance disclosure |
| EcoVadis / ESG downgrade | The EcoVadis Platinum (87/100) is a competitive moat; any environmental incident (effluent, gas leak) at the 16 facilities could reverse this. | Annual sustainability report; media monitoring for Vapi/Jhagadia incidents |
Summary
The risk profile is dominated by balance-sheet and margin risks rather than demand risks. The company is not losing customers, is not facing technological obsolescence, and operates in a sector with 10-12% industry CAGR. The genuine concern is the mismatch between capex, cash flow and returns — Aarti Industries has spent ₹6,407 Cr over 5 years and is producing lower returns today than it did 5 years ago. The risks are all on the operational and financial side, not on the demand side.
9. Investment Thesis
Bull / Base / Bear Scenarios
| Scenario | FY27 EPS (₹) | FY28 EPS (₹) | FY30 EPS (₹) | Target P/E | Target Price (₹) | vs CMP | Action |
|---|---|---|---|---|---|---|---|
| Bull (OPM recovers to 19%, 14% growth) | 18 | 25 | 38 | 22x (in line with PI/SRF premium) | 535 (12m) | +25% | Buy on dips below ₹420 |
| Base (OPM recovers to 16.5%, 11% growth) | 14 | 18 | 26 | 22x (peer median) | 445 (12m) | +4% | Hold; add on weakness |
| Bear (OPM stays at 13-14%, 6% growth) | 11 | 12 | 15 | 18x (de-rating) | 310 (12m) | -28% | Trim if price > ₹420 |
Monitoring checklist (FY27)
- Q1 FY27 OPM: must show a >50 bps QoQ improvement to confirm the capex-payoff thesis; below 14% is a clear negative.
- Quarterly CWIP: should fall below ₹1,800 Cr by Q2 FY27 (from ₹2,030 Cr in Q4 FY26) — Dahej SEZ Phase 2 commissioning.
- Net debt to EBITDA: target <3.0x by FY27 end (FY26 was ~4.3x); a sustained reduction is required to support the re-rating.
- Cumulative FCF: needs to turn positive in FY27 — even +₹200 Cr would be a meaningful inflection after 5 years of negative FCF.
- Effective tax rate: stabilisation at 20-25% rather than the current -15% anomaly, so the headline EPS becomes comparable.
- Customer-funded capex announcement: at least ₹300-400 Cr of customer-funded projects for the new pharma intermediates lines at Dahej.
- DII holding: continuation of the upward trajectory (currently 20.12%) — a fresh high would be a sign of institutional conviction.
Verdict
Aarti Industries is a scale-and-quality specialty chemicals platform caught in the middle of a multi-year capex cycle that has yet to deliver the promised return expansion. The investment case is operationally sound but financially stretched: the topline is compounding, the customer base is strong, the product portfolio is diversified, and the EcoVadis Platinum rating is a genuine moat. What the market is questioning, and rightly so, is the ₹4,966 Cr of borrowings, the 7% ROCE, the -15% effective tax rate, and the -₹346 Cr FY26 free cash flow. The CMP of ₹428 is a 12% premium to the base-case DCF fair value of ₹358 and a -25% discount to the bull case of ₹535. This is not a broken business, but it is a business priced for a recovery that the next 4-6 quarters need to confirm. The risk-adjusted position is a cautious hold with a willingness to add on the first clear FCF-positive print. The story of "Aarti Industries at 38x P/E" makes sense only if FY27-FY28 OPMs reset to 16-18% and ROCE starts climbing back toward 12-14%; absent that, the current multiple is a yield trap. The next 4 quarters will define which scenario plays out.